• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cingulate Inc. - Warrants (NQ:CINGW)

    0.0184 +0.0003 (+1.66%)
    Streaming Delayed Price Updated: 12:33 PM EDT, Jun 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,830
    Open 0.0283
    Bid (Size) 0.0184 (4,500)
    Ask (Size) 0.0282 (1,000)
    Prev. Close 0.0181
    Today's Range 0.0184 - 0.0283
    52wk Range 0.0154 - 0.1750
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
    Data Accepted as Finalist for First Annual Poster Awards 
    From Cingulate Inc.
    Via GlobeNewswire
    News headline image
    Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
    From Cingulate Inc.
    Via GlobeNewswire

    Performance

    YTD
    -69.3%
    -69.3%
    1 Month
    -11.5%
    -11.5%
    3 Month
    -50.1%
    -50.1%
    6 Month
    -53.2%
    -53.2%
    1 Year
    -62.4%
    -62.4%

    More News

    Read More
    News headline image
    Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
    From Cingulate Inc.
    Via GlobeNewswire
    News headline image
    Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
    From Cingulate Inc.
    Via GlobeNewswire
    News headline image
    Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
    From Cingulate Inc.
    Via GlobeNewswire
    News headline image
    Cingulate to Present at 13th Annual LD Micro Invitational
    From Cingulate Inc.
    Via GlobeNewswire
    News headline image
    Cingulate, Indegene to Participate in Benzinga All Live Access Event
    From Cingulate Inc.
    Via GlobeNewswire
    News headline image
    Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
    From Cingulate Inc.
    Via GlobeNewswire
    News headline image
    Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
    From Cingulate Inc.
    Via GlobeNewswire
    News headline image
    Cingulate to Participate in Benzinga All Live Access Event
    From Cingulate Inc.
    Via GlobeNewswire
    News headline image
    Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
    From Cingulate Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Cingulate Inc. - Warrants publicly traded?
    Yes, Cingulate Inc. - Warrants is publicly traded.
    What exchange does Cingulate Inc. - Warrants trade on?
    Cingulate Inc. - Warrants trades on the Nasdaq Stock Market
    What is the ticker symbol for Cingulate Inc. - Warrants?
    The ticker symbol for Cingulate Inc. - Warrants is CINGW on the Nasdaq Stock Market
    What is the current price of Cingulate Inc. - Warrants?
    The current price of Cingulate Inc. - Warrants is 0.0184
    When was Cingulate Inc. - Warrants last traded?
    The last trade of Cingulate Inc. - Warrants was at 06/09/26 12:33 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.